Is the Wegovy pill available on the NHS?
No. You cannot get the Wegovy pill on the NHS at the moment. While the Medicines and Healthcare products Regulatory Agency (MHRA) has now approved the Wegovy pill for weight management in the UK, there are other steps which need to be taken.
Can you get the Wegovy pill on the NHS in the future? Three steps have to happen first:
- MHRA approval (which has been released)
- a review by NICE (the National Institute for Health and Care Excellence) to decide whether the treatment is good value for NHS funding
- a decision by local NHS services on whether to offer it in your area
Oral Wegovy was approved in the US in December 2025, and in the UK in June 2026. NHS access will likely be in 2027 at the earliest.Â
If you are considering the private route the Wegovy pill cost in the UK has been confirmed to start at £129 per month. We are offering a £30 discount to new patients.
What are the current NHS eligibility criteria for Wegovy?
Injectable Wegovy is already available on the NHS. The rules for who qualifies are set out in NICE guidance TA875, published in March 2023. Wegovy pill NHS eligibility will likely follow similar rules once NICE approves it.
To qualify, you need a body mass index (BMI) of 35 or above, plus at least one weight-related health condition. High blood pressure, type 2 diabetes, sleep apnoea or polycystic ovaries are examples. If your BMI sits between 30 and 34.9, you may still be eligible. You still need a weight-related condition, but you may also have to meet your local area’s referral criteria for specialist weight management, which are stricter at a lower BMI.
The cutoff drops by 2.5 BMI points for South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds. Why? Because people from these backgrounds tend to develop weight-related health problems at a lower BMI.
Your GP will refer you to a specialist weight management service, sometimes called a tier 3 or tier 4 service. These are teams of dietitians, psychologists, and doctors. They work with you on diet and exercise alongside any weight loss medication.
NHS funding covers treatment for up to two years. However, if you have not lost at least 5% of your starting body weight within six months of treatment, your clinical team may decide to stop prescribing it for you.
Waiting lists for these services range from around 40 weeks to roughly three years. The waiting time can be region-dependent. The Wegovy pill will not shorten that wait, because you still need the same referral, and the same overstretched services have to accept you. If you think you qualify for NHS treatment, ask your GP about a referral early.
Who should not take the Wegovy pill? Wegovy is not suitable if you or a close family member has had medullary thyroid cancer (MTC), or a condition called multiple endocrine neoplasia type 2 (MEN 2). This is not an exhaustive list; please read the Patient Information Leaflet and speak to your GP before using the Wegovy pill.
What is the new cardiovascular guidance?
In April 2026, NICE published new draft guidance on semaglutide for adults with existing heart disease and a BMI of 27 or above. These patients qualify because of their cardiovascular disease, not just their weight. The goal is to lower their risk of heart attacks and strokes.
Around 1.2 million people in England could qualify under the new guidance. Numbers come from the SELECT clinical trial. It tracked 17,600 adults with heart disease, for roughly three years.
The results showed Semaglutide cut the risk of heart attack, stroke, or death from heart disease by a fifth.
Right now, this only applies to Wegovy injections. But if NICE reviews the pill separately, patients with heart disease and a BMI of 27 or above could access Wegovy tablets through this route instead.
Will the NICE criteria be different for the pill?
As of June 2026, NICE has not started reviewing the Wegovy pill for weight management. When it does, NICE could set new rules for the pill or extend the existing guidance to include it alongside the injection.
What about the 2-year treatment cap?
NICE guidance limits NHS-funded injectable Wegovy to two years, based on cost rather than on clinical evidence. The STEP 5 trial found that people keep losing body weight while they stay on treatment.
It also showed that side effects tend to ease with longer use. STEP 1 trial extension showed the other side. Once people stop, many regain up to two thirds of the weight lost within a year.
NICE has acknowledged the cap problem. A NICE review proposal paper published in February 2025 said the two-year limit may not be right for all patients. Obesity does not go away after two years.
Limiting prescribing to fixed treatment windows does not match how we manage other long-term conditions. You wouldn’t be expected to stop taking blood pressure medication after two years.
If the Wegovy pill costs less than the injection, longer treatment courses may become affordable enough for the NHS to fund. That could mean extending or removing the two-year cap.
Join now
What can I do in the meantime?
Injectable Wegovy is already available, both on the NHS and through private prescribers. If you are trying to lose weight and your BMI is above 30 with a weight-related health condition, you may qualify. Ask your GP about a referral.
If you do not qualify for NHS access, or the wait in your area is too long, a prescriber can discuss private options with you. Wegovy injections are already available privately.
When should I see a doctor?
Ask your GP whether you qualify for injectable Wegovy on the NHS. You need a BMI above 30 and a weight-related health condition.
Book a review with your GP before the two-year treatment cap runs out if you are already on NHS-funded Wegovy. Most people regain weight after stopping semaglutide, so plan ahead.
Talk to your GP about the new NICE cardiovascular guidance if you have a history of heart attack, stroke, or circulation problems and a BMI of 27 or above.
We can also talk you through private options if NHS access is not available to you.
Key takeaways
- Now that the NHRA have approved the Wegovy pill, two things stand between it and NHS access: a NICE review and a local NHS funding decision. Based on current timelines, the earliest realistic date is 2027.
- Injectable Wegovy is available on the NHS now. You need a BMI of 30 or above with a weight-related health condition. You must have a referral to a specialist weight management service. You will be expected to follow a reduced-calorie diet with increased physical activity. NICE TA875 sets out the full criteria.
- New NICE cardiovascular guidance could make around 1.2 million people in England eligible for semaglutide. The aim is to reduce the risk of heart attack and stroke. Right now, this only covers the Wegovy injection.
- Waiting times for specialist weight management services range from 40 weeks to roughly three years, depending on where you live. The pill will not shorten that wait. Ask your GP about a referral early.
- The current price for the launch of the Wegovy pill is from £129 per month, with a £30 discount available.
References
Semaglutide for managing overweight and obesity (TA875), National Institute for Health and Care Excellence, 2023. [Accessed 23 April 2026]
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity (GID-TA11544), National Institute for Health and Care Excellence, 2026. [Accessed 23 April 2026]
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT), New England Journal of Medicine, 2023. [Accessed 23 April 2026]
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial, Nature Medicine, 2022. [Accessed 24 April 2026]
MHRA updates guidance for semaglutide prescribers and patients, Medicines and Healthcare products Regulatory Agency, 2026. [Accessed 23 April 2026]
Accessing Wegovy for weight loss: Everything you need to know, Department of Health and Social Care, 2023. [Accessed 23 April 2026]
Review proposal outcome: semaglutide for managing overweight and obesity (TA875 and TA910), National Institute for Health and Care Excellence, 2025. [Accessed 23 April 2026]
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism, 2022. [Accessed 23 April 2026]
Overweight and obesity management (NG246), National Institute for Health and Care Excellence, 2025. [Accessed 23 April 2026]
Authorship
Authored by Shereen Amin
Pharmacist Independent Prescriber & Medical Writer
GPhC: 2073003
Shereen is a Pharmacist Independent Prescriber and medical writer with over ten years' experience across NHS primary care, digital health and specialist services. She writes evidence-based health content for Simple Online Pharmacy, turning complex clinical information into guidance patients can actually use.
Medically Reviewed by Zahra Qureshi
Senior Pharmacist
GPhC: 2216331
Zahra began her pharmacy career in community pharmacy, building a strong foundation in patient care and medication safety. She joined Simple Online Pharmacy as a locum pharmacist and quickly progressed to a senior role, supporting the pharmacy and operations teams. Zahra is passionate about ensuring patient guidance is safe, clinically sound, and easy to understand, making a positive difference to patients’ lives.
